Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in Oman.

Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases

Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.

Related articles

Hear from an expert on what does Dupixent bring to your practice?

Hear from an expert on what does Dupixent bring to your practice?

Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?

Expert Opinions: Would You Consider A Biologic For A CRSwnp Patient Who Has Had Sinus Surgery?

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

MAT-BH-2300373/V1/JUNE 2023